Liv Longevity Labs
Personalized health plans and biological age insights from at-home blood tests and wearable data.
Website: https://www.liv.health/
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Company | Liv Longevity Labs |
| Tagline | Personalized health plans and biological age insights from at-home blood tests and wearable data. [StartupSeeker, January 2024] |
| Headquarters | Berlin, Germany [StartupSeeker, January 2024] |
| Founded | 2024 [StartupSeeker, January 2024] |
| Stage | Pre-Seed [Wellfound, May 2022] |
| Business model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Funding label | Pre-Seed, total disclosed approximately $2,545,595 [Wellfound, May 2022] |
Links
Publicly reported
- Website: https://www.liv.health/en
- Product: https://app.liv.health/
- The Longview: https://app.liv.health/longview
Summary and Signal
PUBLIC Liv Longevity Labs is a Berlin-based healthtech startup building a direct-to-consumer longevity product around at-home biomarker testing, biological age measurement, and wearable-data integration, and it merits investor attention because the company is positioning itself at the intersection of consumer diagnostics and preventive health behavior change [StartupSeeker, January 2024] [liv.health, retrieved 2024]. The public record is thin, but the company appears to have been founded in 2024 and presents itself as a science-led effort to help users understand pace of aging, organ-specific aging signals, and broader health markers from home-based testing [StartupSeeker, January 2024] [liv.health, retrieved 2024].
The product claim is relatively specific for a company at this stage: Liv markets 100-plus insights from a 10-minute at-home blood test, integrates wearable data, and frames the output as personalized health plans rather than raw lab results alone [liv.health, retrieved 2024] [StartupSeeker, January 2024]. Its clearest point of differentiation, based on public materials, is the use of TruDiagnostic's TruAge framework and named epigenetic clocks including OMICmAge, SYMPHONYAge, and DunedinPACE, which at least gives investors a visible scientific substrate to diligence rather than a generic wellness wrapper [liv.health, retrieved 2024] [TruDiagnostic, retrieved 2026].
Team visibility is better than the structured summary initially suggests, though still incomplete. Public LinkedIn profiles identify Amer Hamzeh as CEO and co-founder, Vassily Eliopoulos as chief medical officer and co-founder, and Dr. Olena Husak as co-founder and CSO, which suggests a founding mix spanning company building and medical or scientific leadership, though the available sources do not establish prior exits, operating track records, or domain-specific commercialization results [LinkedIn, retrieved 2026].
On financing, the evidence is mixed and should be handled conservatively. Structured-source captures associate the company with Y Combinator and HHS and list several funding entries across Wellfound, Tracxn, CB Insights, LinkedIn, and Bounce Watch, but the chronology is internally inconsistent with the reported 2024 founding date, so the only safe takeaway in the public half is that third-party databases indicate some fundraising activity while the precise round history requires direct diligence [Wellfound, May 2022] [Tracxn, retrieved 2026] [CB Insights]. The business model is clearer: Liv sells a consumer subscription priced at €499 per year, with a 90-day guarantee presented on its website [liv.health, retrieved 2024].
Over the next 12 to 18 months, the key questions are less about product narrative than about proof. Investors should watch for evidence that Liv can convert scientific framing into repeatable acquisition, sustain trust in a sensitive health-data workflow, and show that a premium DTC price point can support retention rather than one-off curiosity purchases [liv.health, retrieved 2024] [Luma, January 2025].
No independent source found -- This section relies heavily on company materials and unverified directory or database listings, with only limited independent corroboration for product architecture and team identity.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Funding | Pre-Seed, total disclosed approximately $2,545,595 [Wellfound, May 2022] |
Company Overview
PUBLIC
Liv Longevity Labs presents as an early Berlin longevity startup with a narrow but legible public footprint. The company describes itself through the product rather than through a formal corporate profile: the public site centers on biological age, speed of aging, and a home testing workflow, while a secondary directory listing places the business in Berlin and dates its founding to 2024 [liv.health, retrieved 2024] [StartupSeeker, January 2024].
The chronology is thin, and that matters here. The clearest dated public milestone in the available record is the 2024 company profile describing Liv as a Berlin-based business that integrates wearable data, estimates biological age, monitors 11 organ systems, and offers personalized health plans [StartupSeeker, January 2024]. The company website, also captured in 2024, shows a consumer-facing subscription offer at €499 per year and frames the service around a 10-minute at-home blood test, 100-plus insights, and a 90-day guarantee, which indicates the product was being marketed directly to end users by that point [liv.health, retrieved 2024].
Public evidence on legal entity details, incorporation record, and founding story is limited. No state filing or equivalent corporate registry record is included in the supplied source set, so the overview rests primarily on the company website and one startup directory entry rather than on formal registration documents [liv.health, retrieved 2024] [StartupSeeker, January 2024].
One source, partially checked -- This section relies on the company website and one secondary company directory; no state filing or formal registry document was available in the provided public sources.
The Product and the Stack
Product surface
MIXED The product is presented as a consumer longevity membership built around an at-home test and recurring health interpretation, rather than a general wellness app. On the company website, Liv says it provides "Speed of Aging," "Biological Age" and more than 100 aging insights from a 10-minute blood test at home, priced at €499 per year and paired with a 90-day "Clear Plan Guarantee" [liv.health, retrieved 2024]. Separate product pages and legal pages repeat a narrower capability set: users can measure pace of aging, view insights across 11 organ systems, and connect wearables to manage ongoing measurements [liv.health, retrieved 2024]. A third-party startup directory broadly aligns with that description, characterizing Liv as a Berlin-based platform that integrates wearable data, estimates biological age, monitors 11 organ systems, and provides personalized health plans, although those claims remain secondary and lightly corroborated [StartupSeeker, January 2024].
The technical core, as publicly described, appears to depend substantially on third-party aging models rather than a proprietary assay layer. Liv states that it is powered by TruAge by TruDiagnostic and specifically names DunedinPACE, OMICmAge, and SYMPHONYAge [liv.health, retrieved 2024]. TruDiagnostic's own materials describe OMICmAge as an algorithm for quantifying biological age against chronological age, SYMPHONYAge as a model for reading the age of 11 organ systems, and DunedinPACE as a measure of the rate at which the body is aging [TruDiagnostic, retrieved 2026]. That matters because the current public differentiation rests less on novel biomarker science and more on packaging, consumer experience, and the combination of epigenetic outputs with wearable and planning workflows.
Data handling and user workflow
MIXED The visible user workflow is relatively clear even if the underlying architecture is not. Public login pages show authentication options through Google, Apple, or email [liv.health, retrieved 2024]. Liv's privacy policy adds one useful operational detail: when a user buys from a partner through Liv, payment is processed to the partner's Stripe account, a customer record containing the user's email address and Liv user ID is created there, and the partner can see the purchase as well as the Liv products and services bought from that partner [liv.health, retrieved 2024].
What remains unverified in public is at least as important as what is stated. There is no confirmed public demo, no disclosed performance data, and no public documentation in the supplied sources on sample logistics, lab operations, data security controls beyond the policy language, or whether blood collection and epigenetic analysis are performed directly by Liv or by external partners [liv.health, retrieved 2024]. The evidence does support a coherent consumer proposition, but at this stage it supports the interface and model inputs more clearly than it supports any proprietary technical moat.
No independent source found -- Material product claims rely primarily on company webpages, with partial secondary support from StartupSeeker and methodological corroboration from TruDiagnostic for the named algorithms.
The Market They Are Entering
PUBLIC
The market matters now because consumer interest in longevity has moved from broad wellness claims toward biomarker-backed measurement, but the public record for this specific segment remains thinner than the attention around it would suggest.
For Liv Longevity Labs, a precise TAM, SAM, or SOM cannot be established from the sourced record because no named third-party market study on at-home biological-age testing or consumer longevity diagnostics appears in the materials provided. The safer way to frame the opportunity is through adjacent markets that the company clearly touches: direct-to-consumer health testing, wearable-enabled health monitoring, and preventive longevity services [StartupSeeker, January 2024] [liv.health, retrieved 2024]. That does not yield a defensible market size number on its own, but it does clarify the commercial wedge. Liv is positioned at the intersection of recurring wellness spend, home diagnostics, and quantified-self software, which is a meaningful consumer-health category even if the company-specific segment boundary is still forming [StartupSeeker, January 2024] [Luma, January 2025].
Demand drivers are easier to see than market size. The product framing on Liv's site centers on measurable outputs, biological age, speed of aging, and organ-level insights, rather than general wellness coaching, which aligns with a broader shift in health consumers toward test-based personalization [liv.health, retrieved 2024]. The inclusion of wearable integrations and ongoing plan management suggests a recurring-engagement model rather than a one-off lab purchase, which matters because consumer health products with repeat measurement loops generally have a clearer retention story than single-result tests, if the underlying behavior change proposition holds [liv.health, retrieved 2024] [StartupSeeker, January 2024].
A second tailwind is the increasing visibility of epigenetic clocks and related biological-age frameworks in commercial health products. Liv's public materials tie the service to TruAge by TruDiagnostic and name DunedinPACE, OMICmAge, and SYMPHONYAge as core analytical components [liv.health, retrieved 2024]. TruDiagnostic's own materials describe OMICmAge as a biological-age algorithm, SYMPHONYAge as an organ-system age model covering 11 systems, and DunedinPACE as a measure of the rate of aging [TruDiagnostic, retrieved 2026]. That does not validate Liv's commercial execution, but it does show that the scientific primitives behind the product are part of an emerging commercial toolkit rather than a purely proprietary black box [TruDiagnostic, retrieved 2026].
The nearest adjacent and substitute markets are broader than longevity startups alone. Consumers can pursue similar goals through standard preventive care, premium executive health programs, continuous wearables, nutrition coaching, or standalone at-home test kits that provide narrower biomarker readouts without a biological-age construct [liv.health, retrieved 2024] [StartupSeeker, January 2024]. This matters because Liv is not only competing for spend against other longevity brands, it is also asking customers to choose a more interpretation-heavy product than familiar wellness subscriptions or physician-led diagnostics.
Regulatory and macro forces cut both ways. On the supportive side, home-based testing and digital health engagement are more normalized than they were a few years ago, which lowers adoption friction for consumers who are already comfortable sharing biomarker and wearable data [liv.health, retrieved 2024]. On the constraining side, health-data handling and claims discipline matter more here than in ordinary wellness apps. Liv's privacy policy indicates that partner merchants can see purchase-related customer records and the Liv products or services bought from them, which raises ordinary but material questions around consent, data-sharing clarity, and trust in a category built on intimate health information [liv.health, retrieved 2024]. In practical terms, the category can grow without becoming mainstream overnight, but conversion will likely remain sensitive to scientific credibility, data governance, and whether users believe the outputs lead to actionable behavior change.
| Market frame | Public evidence | What it suggests |
|---|---|---|
| Consumer longevity monitoring | Liv markets biological age, speed of aging, and 11 organ-age insights from an at-home test [liv.health, retrieved 2024] | A distinct consumer-facing longevity product category is emerging, even if size data is sparse |
| Wearable-enabled preventive health | Liv states users can connect wearables and manage relevant measurements [liv.health, retrieved 2024] | The company sits partly inside the broader quantified-self and remote health-monitoring market |
| Personalized health planning | StartupSeeker describes Liv as offering personalized health plans based on biomarkers and wearable data [StartupSeeker, January 2024] | The product also competes with coaching, wellness subscriptions, and preventive health programs |
| Biomarker analytics infrastructure | Liv cites TruAge by TruDiagnostic, including DunedinPACE, OMICmAge, and SYMPHONYAge [liv.health, retrieved 2024] [TruDiagnostic, retrieved 2026] | Part of the value chain depends on third-party aging algorithms becoming commercially accepted |
The table shows a market definition problem more than a market absence problem. Public evidence supports several adjacent demand pools, but not a clean, cited market-size figure for Liv's exact niche, which is the right level of caution at this stage.
One source, partially checked -- Section relies on company materials, one startup directory, one event listing, and TruDiagnostic product documentation; no independent third-party market sizing report was available in the sourced record.
The Competitive Field
Competitive map
MIXED Liv Longevity Labs appears to sit in the consumer longevity-testing segment, but the public record is thin enough that the clearest point of comparison is not a verified peer set so much as a set of adjacent alternatives: direct-to-consumer epigenetic testing, broader wellness subscriptions, and conventional preventive care [StartupSeeker, January 2024] [liv.health, retrieved 2024].
On the company's own site, Liv frames the offer around biological age, pace of aging, 11 organ-system ages, and wearable-data integration, delivered through an at-home test and a yearly subscription priced at €499 [liv.health, retrieved 2024]. StartupSeeker's profile points in the same direction, describing a Berlin-based platform that estimates biological age, monitors 11 organ systems, and generates personalized health plans [StartupSeeker, January 2024]. That places Liv closest to the consumer biomarker and longevity-testing cohort, where the product promise is ongoing interpretation rather than a one-time lab result.
The adjacent substitute set is broader and, in practice, likely more important than startup-to-startup rivalry. A health-conscious consumer can spend against a primary-care checkup, a specialty longevity clinic, a generic wearable subscription, or a single-purpose biological-age test sold without a recurring planning layer [liv.health, retrieved 2024] [StartUs Insights]. Liv's challenge is that these substitutes are not interchangeable scientifically, but they do compete for the same wallet and attention.
One useful reference point is TruDiagnostic, because Liv states that it is powered by TruAge and cites the OMICmAge, SYMPHONYAge, and DunedinPACE clocks on its homepage [liv.health, retrieved 2024]. TruDiagnostic's own materials describe OMICmAge as a biological-age algorithm, SYMPHONYAge as a measure across 11 organ systems, and DunedinPACE as a measure of aging rate [TruDiagnostic, retrieved 2026]. That suggests Liv may be competing less on proprietary assay science today and more on packaging, interpretation, user experience, and consumer engagement around third-party science.
Edge and durability
MIXED The most tangible edge visible in public materials is product assembly rather than proprietary platform control.
Liv combines several ingredients that consumers usually have to source separately: an at-home aging test, multiple epigenetic-age outputs, wearable integration, and a personalized action-plan layer [liv.health, retrieved 2024] [StartupSeeker, January 2024]. If executed well, that can reduce friction. A user who wants a single answer to "how fast am I aging and what should I do next" may prefer an integrated experience over buying a lab test from one provider and building a self-directed regimen elsewhere.
The problem is durability. The underlying clock framework appears to come from TruDiagnostic rather than from a Liv-owned biomarker model, at least in the public materials available today [liv.health, retrieved 2024] [TruDiagnostic, retrieved 2026]. That makes the edge perishable unless Liv can build defensibility in areas the source set does not yet confirm, such as superior retention, better recommendation quality, a trusted clinical layer, or a proprietary longitudinal dataset created through repeat testing and wearable behavior data.
There is a modest commercial wedge in the subscription design. The homepage advertises more than 100 insights, a €499 annual price point, and a 90-day guarantee, which indicates an effort to make a relatively technical category easier to buy in consumer terms [liv.health, retrieved 2024]. Still, those are merchandising choices, not deep moats. A well-capitalized testing brand or clinic network could likely replicate the framing faster than it could replicate a differentiated dataset.
Exposure points
MIXED Liv looks most exposed wherever scientific credibility, channel ownership, or founder-level trust matter more than interface quality.
First, TruDiagnostic has a specific advantage in the underlying science stack that Liv itself cites. If consumers or partners decide they would rather buy directly from the source of the clocks, the intermediary layer becomes harder to defend [TruDiagnostic, retrieved 2026] [liv.health, retrieved 2024]. Public evidence does not show that Liv controls the assay infrastructure or the proprietary age algorithms, which limits how much of the technical value chain it owns.
Second, the company does not appear, from the available sources, to own an obvious distribution channel. There is no verified evidence here of employer contracts, payer reimbursement, hospital distribution, or named clinic partnerships. The privacy policy does mention partners transacting through Liv and being able to see customer purchase records for Liv products bought from them, which implies some partner-linked commerce model, but not enough public detail to treat that as proven channel strength [liv.health, retrieved 2024].
Third, Liv may face a category ceiling if the buyer ultimately wants medical advice rather than insight generation. The current materials emphasize measurements, organ-age readouts, and personalized plans, but the public evidence does not establish a regulated care-delivery footprint or a clinical-services network [liv.health, retrieved 2024] [StartupSeeker, January 2024]. That leaves room for preventive-care incumbents and longevity clinics to position themselves as the higher-trust option for users making consequential health decisions.
Most plausible 18-month scenario
MIXED The next 18 months likely turn on whether consumer longevity testing consolidates around science owners or around brands that make the science easy to use.
The most plausible near-term outcome is that category leaders with direct ownership of biomarker IP, or at least stronger brand recognition around validated clocks, keep the upper hand in customer acquisition. On the evidence available, TruDiagnostic is the clearest named winner if the market rewards scientific provenance above all else, because its public materials anchor the underlying algorithms Liv references [TruDiagnostic, retrieved 2026] [liv.health, retrieved 2024]. In that scenario, application-layer brands need either lower acquisition costs, stronger retention, or clinically credible guidance to avoid compression.
The corresponding loser if that dynamic hardens is any consumer-facing layer that depends on similar third-party measurement primitives without a visible distribution moat. Liv could fall into that bucket if its differentiation remains limited to packaging the same clocks with a cleaner interface and a yearly plan [liv.health, retrieved 2024]. The more constructive version of the same scenario is that Liv uses wearable integration and repeated testing to build a useful longitudinal dataset and habit loop. Public evidence does not yet show that outcome, but that is the path that would make the company harder to displace than a standard test reseller.
No independent source found -- The section relies primarily on company materials and third-party directory descriptions, with one relevant named ecosystem reference point in TruDiagnostic.
Opportunity
PUBLIC
The prize here is straightforward: if Liv turns a one-off longevity test into a trusted, recurring operating system for personal preventive health, the company could move from a niche biomarker product to a durable consumer health platform in a category that still lacks a widely recognized default brand [liv.health, retrieved 2024] [StartupSeeker, January 2024].
The headline opportunity is larger than the current product surface suggests. Public materials indicate that Liv is not positioning itself as a single biological-age score, but as a subscription service that combines an at-home test, wearable-data integration, personalized plans, and repeated measurement across biological age, pace of aging, and 11 organ systems [liv.health, retrieved 2024] [StartupSeeker, January 2024] [TruDiagnostic, retrieved 2026]. That matters because consumer health categories tend to become meaningful businesses when they shift from episodic testing to ongoing behavior management. Liv's annual price point of €499, alongside a stated guarantee, implies an attempt to build recurring engagement rather than one-time diagnostics [liv.health, retrieved 2024]. The reachability of that outcome is still only partially evidenced, but the product architecture, recurring pricing, and use of recognized epigenetic algorithms make the ambition more concrete than a generic wellness app [TruDiagnostic, retrieved 2026] [liv.health, retrieved 2024].
A few upside paths are visible from the limited public record.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Consumer longevity subscription | Liv becomes a premium European subscription for consumers who want repeat biological-age tracking and personalized guidance, with retention driven by measurable progress over time | Broader awareness of epigenetic testing and biomarker-led preventive health, plus continued consumer willingness to pay for recurring wellness programs [Luma, January 2025] [liv.health, retrieved 2024] | The site already packages the service as a yearly product with repeated measurement, guarantees, and integrated insights rather than a one-time report [liv.health, retrieved 2024] |
| Measurement layer for partner-led distribution | Liv grows through clinics, coaches, or wellness partners that use Liv as the front-end relationship and transaction layer for customers | Expansion of partner channels and resale relationships, suggested by Liv's privacy language around partner purchases and partner-visible records [liv.health, retrieved 2024] | The privacy policy explicitly contemplates partner-mediated purchases and partner visibility into customer purchases, which suggests some distribution design beyond pure direct web acquisition [liv.health, retrieved 2024] |
| Trusted interface on top of validated aging clocks | Liv becomes a consumer-facing brand that translates complex epigenetic science into a usable health product, while relying on established third-party clocks for scientific credibility | Wider recognition of clocks such as DunedinPACE, OMICmAge, and SYMPHONYAge, especially as they accumulate publication history and commercial use [TruDiagnostic, retrieved 2026] | Liv publicly anchors its product in named algorithms rather than proprietary black-box claims, which can help a young brand borrow trust from established scientific tools [liv.health, retrieved 2024] [TruDiagnostic, retrieved 2026] |
The compounding mechanism, if it emerges, is a mix of longitudinal data, habit formation, and channel expansion. Liv asks users to connect wearables, take an at-home test, and return for updated measurements over time [liv.health, retrieved 2024] [StartupSeeker, January 2024]. In practice, that could create a useful feedback loop: more recurring users produce more longitudinal observations, better longitudinal observations improve personalization and progress tracking, and better perceived personalization supports retention at subscription pricing. A second layer of compounding could come from partners if those relationships are active at scale, because each partner would lower customer-acquisition friction while increasing the value of the shared data and service history within Liv's ecosystem [liv.health, retrieved 2024]. None of that flywheel is proven publicly yet, but the product and policy design point in that direction.
The size of the win is easiest to frame through category logic rather than current company metrics, which remain sparse. If Liv were to become one of Europe's recognized premium preventive-health subscriptions, the economic model could resemble a high-retention consumer health platform more than a test-kit vendor, with value driven by annual renewals, data continuity, and software-like engagement [liv.health, retrieved 2024]. A concrete public comparable is not established in the available source set, so any valuation framing has to stay conditional. On that basis, a reasonable upside case is that a scaled version of this model could support venture-scale value, potentially in the hundreds of millions of euros (scenario, not a forecast), if Liv proves that consumers will renew around longitudinal aging data and if partner-led distribution lowers acquisition costs enough to make the subscription durable. The limiting factor in public analysis is not the conceptual upside, but the absence of corroborated traction data.
No independent source found -- This section relies primarily on company materials and a startup directory, with product design and scenario analysis grounded in public website language and third-party descriptions rather than independently corroborated operating metrics.
Sources
Publicly reported
[StartupSeeker, January 2024] Liv Longevity Labs | https://startup-seeker.com/company/liv~health
[liv.health, retrieved 2024] Know how fast you’re really aging | Liv Longevity Labs | https://www.liv.health/en
[TruDiagnostic, retrieved 2026] About TruAge | https://www.trudiagnostic.com/about-truage
[LinkedIn, retrieved 2026] Amer Hamzeh - CEO & Co-Founder at Liv | https://www.linkedin.com/in/amerhamzeh/
[Wellfound, May 2022] Liv Longevity Labs | https://wellfound.com/company/liv-health
[Tracxn, retrieved 2026] Liv Longevity Labs | https://tracxn.com/d/companies/liv-health
[Luma, January 2025] Liv Longevity Labs · Events Calendar | https://luma.com/liv
[CB Insights] Liv Longevity Labs | https://www.cbinsights.com/company/liv-longevity-labs
[StartUs Insights] TruAge, an at-home cellular aging test that analyzes DNA methylation patterns from saliva to generate biological age | https://www.startus-insights.com/innovators-guide/longgevity-startups/
[liv.health, retrieved 2024] The Longview - Liv Longevity Labs | https://app.liv.health/longview
[liv.health, retrieved 2024] Privacy policy | Liv Longevity Labs | https://www.liv.health/en/legal/privacy
Articles about Liv Longevity Labs
- A €499 Annual Subscription Puts Three Epigenetic Clocks in a Berlin Home — The Berlin-based DTC health startup is betting consumers will pay for peer-reviewed epigenetic clocks like DunedinPACE and SYMPHONYAge.